Senores Pharmaceuticals Limited has informed the Exchange regarding change in the Senior Management Personnel (SMP) of the Company
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals reported strong Q1 FY26 results (quarter ended June 30, 2025), with consolidated total income rising 72% year-on-year to Rs. 138 crore and profit after tax (PAT) jumping 95% YoY to Rs. 21.3 crore. EBITDA grew 60% YoY to Rs. 34 crore, with EBITDA margin at 24.8% and PAT margin expanding to 15.4%. Regulated Markets revenue surged 69% YoY to Rs. 90 crore, while Emerging Markets revenue grew 32% to Rs. 29 crore. The company also categorized Mr. Jignesh Shashikant Desai, President-Finance, as Senior Management Personnel (SMP) effective July 23, 2025, recognizing his 30+ years of finance experience. The Q1 results have been reviewed by statutory auditors Pankaj R. Shah and Associates with an unqualified limited review report.
Strong quarter with high-double-digit profit growth and margin expansion signals healthy business momentum, likely to be viewed positively by shareholders. The SMP categorization is a routine governance update with no negative implications.